SYM FINANCIAL Corp Buys New Shares in R1 RCM Inc. (NASDAQ:RCM)

SYM FINANCIAL Corp bought a new stake in shares of R1 RCM Inc. (NASDAQ:RCM) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 21,008 shares of the healthcare provider’s stock, valued at approximately $264,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new position in R1 RCM during the first quarter valued at $27,000. ANTIPODES PARTNERS Ltd bought a new stake in R1 RCM during the second quarter valued at about $86,000. QRG Capital Management Inc. bought a new stake in R1 RCM during the first quarter valued at about $132,000. Caas Capital Management LP bought a new stake in R1 RCM during the fourth quarter valued at about $148,000. Finally, CIBC Asset Management Inc bought a new stake in R1 RCM during the second quarter valued at about $149,000. 61.10% of the stock is currently owned by hedge funds and other institutional investors.

R1 RCM Price Performance

Shares of RCM opened at $14.12 on Friday. The firm has a fifty day moving average price of $13.58 and a 200-day moving average price of $13.01. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $5.95 billion, a P/E ratio of -176.50 and a beta of 0.84. R1 RCM Inc. has a 12-month low of $8.87 and a 12-month high of $16.68.

R1 RCM (NASDAQ:RCM) last issued its earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. R1 RCM had a negative return on equity of 1.44% and a negative net margin of 1.68%. The business had revenue of $627.90 million during the quarter, compared to analyst estimates of $633.10 million. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities research analysts expect that R1 RCM Inc. will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price target on shares of R1 RCM in a report on Monday, July 22nd. Morgan Stanley cut R1 RCM from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 8th. Robert W. Baird reissued an “outperform” rating and set a $18.00 price target on shares of R1 RCM in a report on Tuesday, July 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $19.00 price target on shares of R1 RCM in a report on Friday, June 28th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on R1 RCM from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, July 9th. Thirteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $15.41.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.